Gaudium IVF and Women Health Limited has announced an earnings conference call to discuss the audited standalone and consolidated financial statements for the quarter and year ended March 31, 2026. The meeting is scheduled for Friday, May 29, 2026, at 12:00 P.M. IST, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The board meeting to consider these financial results was previously scheduled for Thursday, May 28, 2026. The upcoming conference call will allow management to elaborate on the company's performance for the fiscal year.

Conference Call Details

Participants can join the discussion via pre-registration or operator-assisted dial-in. The company has provided a Universal Access Number and international toll-free lines for attendees.

The Universal Access Number for India is +91 22 6280 1102 or +91 22 7115 8003. Participants are requested to dial in a few minutes in advance.

Management Participants

The call will feature key leadership figures from the company, including:

• Dr. Manika Khanna, Chairperson & Managing Director
• Dr. Peeyush Khanna, Whole-Time Director
• Mr. Rakesh K. Sharma, Chief Financial Officer

Further information regarding the earnings call and financial results will be available on the company's official website.

Gaudium IVF and Women Health Limited has issued a clarification to stock exchanges regarding recent share price movements, confirming that the volatility is purely market driven with no undisclosed material information pending. The company responded to specific queries from both BSE and NSE on April 16, 2026, addressing concerns about significant price fluctuations in its scrip.

Regulatory Compliance and Disclosure

The gaudium ivf & women health management emphasized its commitment to regulatory compliance, stating that all material events and information affecting company operations and performance have been disclosed to stock exchanges within stipulated timeframes. The company confirmed adherence to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency in all material disclosures.

Exchange Communications

The clarification was issued in response to formal communications from both major stock exchanges:

Company Position on Price Movement

The company categorically stated that there is no undisclosed price sensitive information or impending announcements that could influence share price or volume behavior. Management attributed the recent price movements entirely to market forces, dismissing speculation about any underlying corporate developments or material events that have not been publicly disclosed.

Future Disclosure Commitments

Gaudium IVF and Women Health Limited reaffirmed its commitment to maintaining transparency with stakeholders and regulatory bodies. The company assured continued prompt disclosure of all material events, information, and corporate actions as required under SEBI regulations. This commitment underscores the company's dedication to maintaining investor confidence through transparent communication practices.

The clarification was signed by Company Secretary and Compliance Officer Naveen Kumar, emphasizing the formal nature of the response and the company's commitment to regulatory compliance in addressing market concerns about share price volatility.